Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1Burkitt Lymphoma 1Breast Carcinoma In Situ 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Advanced Cancer 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Ranitidine × Clear all
NCT01287520 2019-02-25

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
41 enrolled 28 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡